KDM1A and breast carcinoma: In terms of breast cancer, the LSD-1 inhibitor INCB059872 together with immunotherapy such as anti-programmed cell death ligand 1 drugs (anti-PD-L1) enhanced the efficacy of such immunotherapy agents and general anti-tumour efficacy [10].